Fabio Cartabellotta

Plain English
This study looked at how well hospitals follow treatment guidelines for patients with type 2 diabetes while they are admitted to internal medicine units. Researchers found that while an educational program improved guideline adherence from 1909 patients to 1662 patients, it did not significantly change blood sugar levels at discharge. This is important because better adherence to treatment guidelines can lead to better overall care for diabetic patients, even if it doesn't show immediate effects on blood sugar control. Who this helps: This helps patients with type 2 diabetes in hospitals.

Plain English
This study looked at how effective endoscopic ultrasound-guided gallbladder drainage is for lowering bilirubin levels in patients with a type of bile duct blockage caused by cancer. Researchers found that this method can successfully normalize bilirubin levels, which is essential before starting chemotherapy. This is important because high bilirubin can lead to serious health issues and prevent effective cancer treatment. Who this helps: Patients with distal malignant biliary obstruction who need chemotherapy.

Plain English
This research paper looks at how hepatitis C treatments have changed from older therapies like interferon, which had low success rates and many side effects, to today's advanced treatments known as direct-acting antivirals (DAAs). The newer DAAs can cure over 95% of hepatitis C cases, work on all virus strains, have shorter treatment times, and cause fewer side effects compared to previous therapies. This matters because it makes treatment more effective and accessible for patients, improving their chances of recovery and quality of life. Who this helps: Patients with hepatitis C.

Plain English
The SINTESI Project in Sicily aimed to eliminate hepatitis C virus (HCV) among prisoners by providing easy access to testing and treatment in all 23 prisons. Out of nearly 6,000 prisoners, 85.4% agreed to get tested for HCV, and 4.8% tested positive. Of those who tested positive, 87.9% completed a treatment that led to an 86.7% success rate in clearing the virus, showing that targeted programs can effectively help vulnerable populations manage and overcome HCV. Who this helps: This benefits prisoners at risk of hepatitis C.

Plain English
This study looked at how common Hepatitis C virus (HCV) infections are among patients at a hospital in Sicily. Out of 15,550 patients, 469 (or 3%) tested positive for HCV antibodies, with the rate increasing for older age groups—up to 6.4% in those over 80. The findings tell us that screening can effectively identify those at risk for serious liver disease and help prevent the spread of the infection. Who this helps: This research benefits patients, particularly older adults and those at risk of HCV infection.

Plain English
In this study, researchers described a rare case involving a 68-year-old man who developed a type of spinal inflammation called myelitis after a pneumococcal infection. The patient initially presented with fever and motor weakness and later developed arthritis in his ankle. After treatment with antibiotics and steroids, he showed some improvement in his nerve function and the arthritis symptoms went away with additional medication, emphasizing the need to consider infections as possible causes for neurological conditions. Who this helps: This information benefits doctors and healthcare providers in identifying and treating unusual complications from infections.

Plain English
This study focused on improving care for patients with esophagogastric junction and gastric cancer by creating and implementing a detailed plan for how doctors should work together. The researchers created a clinical pathway that received strong agreement from experts and was validated by a certification body to ensure it met high standards. The importance of this work lies in providing a clear method to enhance patient treatment and outcomes, making the process smoother across different hospitals. Who this helps: This helps patients with esophagogastric junction and gastric cancer, as well as their doctors.

Plain English
This study looked at the impact of successfully treating hepatitis C with direct-acting antiviral drugs (DAAs) on the long-term health of over 4,300 patients, most of whom had liver complications. Researchers found that 94.7% of patients achieved a sustained response to treatment, which was linked to a significantly lower risk of dying from liver disease (only 1.4% died during the study) and cardiovascular issues, regardless of liver damage. This is important because it shows that effectively treating hepatitis C can lead to better survival rates for these patients. Who this helps: This helps patients with hepatitis C and their doctors in making informed treatment decisions.

Plain English
This study looked at how to better manage hepatitis C (HCV) infections, which affect about 71 million people globally. With new treatments, over 95% of patients can be cured, preventing serious liver damage and reducing deaths related to the disease. However, there’s still a need for more effective screening and treatment access for all patients, regardless of how advanced their liver disease is. Who this helps: This helps HCV patients who need better access to treatments and screenings.

Plain English
This study looked at how direct-acting antivirals (DAAs) affect the survival of patients with liver cirrhosis caused by hepatitis C who were successfully treated for early liver cancer. Among 102 patients treated with DAAs, only 6.9% died, and 5.9% experienced severe liver issues, compared to better outcomes than a similar group of untreated patients. Overall, DAAs significantly improved survival rates and lowered liver complications, although they didn’t reduce the chance of cancer returning. Who this helps: Patients with hepatitis C and liver cancer.

Plain English
This study focused on finding a simpler way to determine if patients with cirrhosis due to hepatitis C have large esophageal varices (swollen veins in the esophagus that can cause bleeding) without needing an invasive procedure called an endoscopy. Researchers evaluated 1,381 patients and found that their new RESIST-HCV criteria, which are based on common lab tests like platelet count and albumin levels, accurately identified those at risk. Specifically, the new criteria allowed over 30% of patients to avoid endoscopy while maintaining high accuracy in predicting risk, with negative predictive values of 99.2% in one group of patients. Who this helps: This helps cirrhosis patients by reducing the need for invasive procedures.

Plain English
This study looked at how often liver cancer, known as hepatocellular carcinoma (HCC), occurred in patients with liver cirrhosis caused by the hepatitis C virus after they were treated with new antiviral medications. Out of 2,249 patients, only 3.5% developed HCC during an average follow-up of 14 months. The researchers found that having a sustained response to treatment significantly reduced the risk of developing cancer, especially for patients with certain health indicators like better blood protein and platelet levels. Who this helps: This information benefits patients with hepatitis C and their doctors by providing a clearer understanding of cancer risks after treatment.

Plain English
This study looked at whether treating hepatitis C with new antiviral drugs affected the chances of early return of liver cancer in patients who had previously been cured. They followed 143 patients and found that 29% experienced a return of cancer within 18 months, which is similar to rates seen in patients who didn't receive the antiviral treatment. The study highlights that, while the antiviral treatment successfully clears the virus, it does not eliminate the risk of cancer coming back, especially in those with larger tumors or a prior history of recurrence. Who this helps: This information is important for liver cancer patients, doctors, and healthcare providers managing treatment strategies.

Plain English
The HCV Sicily Network studied the management and treatment of chronic hepatitis C in Sicily, where around 30,000 people are affected. Between March 2015 and September 2016, nearly 10,000 patients were monitored, and 87.8% of those who completed the treatment showed a positive response, meaning the virus was no longer detectable in their bodies. This system helps track treatments, ensuring more people can effectively receive care despite high costs. Who this helps: Patients with chronic hepatitis C and healthcare providers.

Plain English
This research examined the health of patients with hepatitis C who had normal liver enzyme levels but were still infected with the virus. Among 45 patients studied for about 15 years, 25 continued to have normal enzyme levels, but two eventually developed serious liver damage, while others had fluctuations in enzyme levels and three developed liver cirrhosis over time. The study found that older age, higher body mass index, and more severe liver damage at the start were linked to a greater risk of developing cirrhosis. Who this helps: This information is valuable for doctors monitoring hepatitis C patients, especially those with normal liver enzymes.

Plain English
This study looked at how well a test that measures calprotectin in stool samples can identify chronic diarrhea caused by inflammatory bowel disease (IBD) as opposed to other problems like irritable bowel syndrome. They tested 120 patients (70 adults and 50 children) with chronic diarrhea and found that the calprotectin test was quite accurate: it correctly identified IBD cases in adults 100% of the time and had a sensitivity of 70% in children, meaning it could miss some cases. It's important because accurate diagnosis is crucial for effective treatment, especially for conditions like IBD, and helps avoid unnecessary procedures. Who this helps: This helps patients suffering from chronic diarrhea, particularly those with IBD.

Plain English
This study compared two treatments for patients with chronic hepatitis C who didn’t get better with previous interferon-alpha therapy. The researchers found that while only 1 out of 24 patients improved with just interferon-alpha, 12 out of 48 patients improved when given a combination of interferon-alpha and ribavirin. This matters because combination therapy was more effective, giving hope to patients who didn’t respond to earlier treatments. Who this helps: Patients with chronic hepatitis C who have not responded to other treatments.